A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2018
At a glance
- Drugs Evinacumab (Primary)
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 04 Sep 2018 Planned End Date changed from 29 Jan 2021 to 22 Jan 2021.
- 04 Sep 2018 Planned primary completion date changed from 19 May 2020 to 14 May 2020.
- 04 Sep 2018 Status changed from not yet recruiting to recruiting.